||1U54CA260582-01 Interpret this number
||Ohio State University
||Center for Serological Testing to Improve Outcomes From Pandemic COVID-19 (Stop-COVID)
Overall Project Summary
Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied
sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-
COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission,
immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving
population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests,
developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2
exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will
understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune,
host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center
investigators will also identify best practices for communication of test results and information about COVID-19
to improve understanding of risk, transmission, and protection, while reducing access barriers to testing.
The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource
cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities
as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform
first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization
assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will
provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and
psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel
serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first
responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this
presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and
immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2
and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also
will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune
responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information
around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices
in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from
disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID
infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries
and their translation into actionable strategies for implementation across all groups affected by COVID-19.
SARS-CoV-2 Spreads through Cell-to-Cell Transmission.
, Evans J.P.
, King T.
, Zheng Y.M.
, Oltz E.M.
, Whelan S.P.J.
, Saif L.
, Peeples M.E.
, Liu S.L.
bioRxiv : the preprint server for biology, 2021-06-01; , .
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
, Dravid P.
, Zhang Y.
, Trivedi S.
, Li A.
, Harder O.
, Kc M.
, Chaiwatpongsakorn S.
, Zani A.
, Kenney A.
, et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021-03-23; 118(12), .
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
, Evans J.P.
, Pearson R.
, Qu P.
, Zheng Y.M.
, Robinson R.T.
, Hall-Stoodley L.
, Yount J.
, Pannu S.
, Mallampalli R.K.
, et al.
JCI insight, 2020-11-19; 5(22), .